| 0 (0%) | 11-30 07:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.1 | 1-year : | 7.27 |
| Resists | First : | 5.22 | Second : | 6.23 |
| Pivot price | 4  |
|||
| Supports | First : | 3.59 | Second : | 2.99 |
| MAs | MA(5) : | 3.8 |
MA(20) : | 4.26 |
| MA(100) : | 4.53 |
MA(250) : | 2.85 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 12.7 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 6.75 | Low : | 1.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATAI ] has closed above bottom band by 38.8%. Bollinger Bands are 27.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.8 - 3.83 | 3.83 - 3.85 |
| Low: | 3.64 - 3.67 | 3.67 - 3.69 |
| Close: | 3.71 - 3.75 | 3.75 - 3.79 |
Tue, 25 Nov 2025
H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion - Yahoo Finance
Wed, 05 Nov 2025
Latham & Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech to Form AtaiBeckley - Latham & Watkins LLP
Wed, 05 Nov 2025
Atai Life Sciences N.V. (ATAI) Stock: Sharp Drop Follows Bold Merger Creating AtaiBeckley Biopharma Powerhouse - parameter.io
Wed, 05 Nov 2025
ATAI Life Sciences Files Prospectus for Share Resale - TipRanks
Wed, 05 Nov 2025
AtaiBeckley (NASDAQ: ATAI) finalizes all-share deal; funding expected into 2029 - Stock Titan
Tue, 04 Nov 2025
ATAI Life Sciences shareholders approve acquisition of Beckley Psytech and redomiciliation - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.6319e+008 (%) |
| Held by Institutions | 1.5472e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.02e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.83 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 796.5 % |
| Return on Equity (ttm) | -29 % |
| Qtrly Rev. Growth | 3.02e+006 % |
| Gross Profit (p.s.) | 102.76 |
| Sales Per Share | -48.12 |
| EBITDA (p.s.) | 1.45283e+006 |
| Qtrly Earnings Growth | -1.0052e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -4.69 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 0 |
| Dividend | 1.388e+007 |
| Forward Dividend | 1.612e+007 |
| Dividend Yield | 356812000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|